

Paris, France, March 1, 2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

Article L233-8-II of the Commercial code

Article 223-16 of the General Regulations of the Autorité des Marchés Financiers

Market: Euronext Paris
 Compartment: Compartment C
 ISIN code: FR0012633360
 Website: www.cellnovo.com

Date	Total number of shares	Total number of voting rights	
		Total gross voting rights ⁽¹⁾	Total net voting rights ⁽²⁾
February 28, 2019	17,927,660	17,927,660	17,908,507

- (1) The number of gross voting rights (or “theoretical” number of voting rights) serves as the basis for calculating the threshold crossings. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.
- (2) The number of net voting rights (or voting rights “exercisable at the General Assembly”) is calculated without taking into account the shares with suspended voting rights. It is disclosed for the proper information of the general public, in accordance with the AMF recommendation dated July 17, 2007.

About Cellnovo (Euronext: CLNV)

Cellnovo Group is global innovative medical technology company supporting the needs and desires of people with type 1 diabetes. Cellnovo has developed and markets a novel diabetes management system, which is a connected platform that aims to make life easier for people with type 1 diabetes. Cellnovo’s insulin delivery system comprises a locked-down Android™ smartphone that communicates via Bluetooth® with a discreet, wearable micro-pump. This unique system allows optimal management of insulin dosing and delivery while ensuring freedom of movement and peace of mind. Thanks to the transmission of data in real time, the patient’s status can be seamlessly monitored by family members and healthcare professionals. Cellnovo is currently participating in several major Artificial Pancreas projects with TypeZero, PEPPER and Diabeloop, to develop fully automated, closed-loop insulin delivery systems.

For more information go to www.cellnovo.com

Cellnovo is listed on Euronext, Compartment C
 ISIN: FR0012633360 – Ticker: CLNV





The first connected diabetes management platform

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Dusan Oresansky
+ 33 1 44 71 94 92
cellnovo@newcap.eu

NewCap

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu